RepliCel Life Sciences Inc (REPCF)
0.0428
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
RepliCel Life Sciences Revenue (Quarterly): 0.0659M for Sept. 30, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 0.0659M |
| June 30, 2023 | 0.0657M |
| March 31, 2023 | 0.0654M |
| December 31, 2022 | 0.0651M |
| September 30, 2022 | 0.0677M |
| June 30, 2022 | 0.0692M |
| March 31, 2022 | 0.0698M |
| December 31, 2021 | 0.0702M |
| September 30, 2021 | 0.0702M |
| June 30, 2021 | 0.072M |
| March 31, 2021 | 0.0698M |
| December 31, 2020 | 0.0679M |
| September 30, 2020 | 0.0664M |
| June 30, 2020 | 0.0638M |
| March 31, 2020 | 0.066M |
| December 31, 2019 | 0.067M |
| September 30, 2019 | 0.0669M |
| June 30, 2019 | 0.0472M |
| March 31, 2019 | 0.0475M |
| December 31, 2018 | 0.1268M |
| September 30, 2018 |
| Date | Value |
|---|---|
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | 3.966M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0472M
Minimum
Jun 2019
0.072M
Maximum
Jun 2021
0.0664M
Average
0.067M
Median
Revenue (Quarterly) Benchmarks
| Acasti Pharma Inc | -- |
| Aurinia Pharmaceuticals Inc | 45.10M |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 0.145M |
| InMed Pharmaceuticals Inc | 1.240M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.61M |
| Total Expenses (Quarterly) | 0.3084M |
| EPS Diluted (Quarterly) | -0.0075 |
| Enterprise Value | 2.791M |
| Profit Margin (Quarterly) | -925.7% |
| Earnings Yield | -0.44% |
| Normalized Earnings Yield | 23.15 |